ZYLOXTB-B News

Guichuang Tongqiao (02190.HK): Intensive launch of a variety of new products drives performance growth and further increases market share in collection and release

東北證券Mar 26 00:00

Guichuang Tongqiao (2190.HK): Revenue growth slightly exceeds expectations in 2023, and the dense net stent is expected to be approved within the year

浦銀國際Mar 22 00:00

Guichuang Tongqiao-B (02190.HK): Performance is in line with expectations, domestic alternatives continue to be verified

中金公司Mar 22 00:00

Guichuang Tongqiao-B (02190.HK): Investor Day shows management confidence and performance is expected to continue to be realized

中金公司Nov 30, 2023 00:00

Homecoming Bridge (2190.HK): New products across the two core tracks of Shinsuke and Outer Zhou have entered an intensive approval period

浦銀國際Nov 24, 2023 00:00

Changes in Hong Kong stocks 丨 Guichuang Tongqiao once rose more than 13% and received a “overfit” rating from Morgan Stanley. The target price was HK$18.2

Gelonghui FinanceSep 25, 2023 11:51

Guoyuan International: Returning to Chuangtongqiao-B (02190) “Buying” ratings for neurologic and peripheral vascular intervention leaders is expected to usher in rapid growth

Zhitong FinanceMay 6, 2023 13:00

Guichuang Tongqiao-B (02190.HK): Achieving Steady Growth Under the Epidemic, Harvesting Has Gradually Been Implemented to Accelerate Domestic Substitution

興業證券Apr 14, 2023 12:57

Guichuang Tongqiao-B (02190.HK): 2022 results are in line with expectations, import substitution is here

中金公司Mar 30, 2023 00:00

Guichuang Tongqiao-B (02190.HK): Neuro+Peripheral Dual Wheel Drive Towards Pan-vascular Interventional Platform Enterprise

中金公司Oct 16, 2022 00:00

Guichuang Tongqiao-B (02190.HK) 2022 Interim Report Review: High Revenue Side Growth Slightly Exceeds Expectations Multiple Product Layouts Can Be Expected in the Future

中信證券Aug 25, 2022 20:01

Guichuang Tongqiao (02190.HK): Neuro and peripheral businesses achieved high growth in the first year of commercialization

興業證券Apr 4, 2022 00:00

Guichuang Tongqiao-B (02190.HK) Company Comment: The commercialization of 2021 performance exceeding expectations has been initially verified

天風證券Mar 17, 2022 13:27

Guichuang Tongqiao-B (02190.HK): The combination of neuro+peripheral intervention is expected to grow into a platform-based company

興業證券Aug 19, 2021 00:00

Guichuang Tongqiao-B (02190.HK): A leader in neurological intervention and peripheral vascular intervention

天風證券Aug 2, 2021 00:00

Futu Securities: Guichuang Tongqiao (2190.HK) — IPO Review

富途證券Jun 23, 2021 15:27

IPO Preview: Guichuang Tongqiao (2190.HK)

光大新鴻基Jun 22, 2021 00:00

IPO News: Guichuang Tongqiao Medical Technology Co., Ltd. (2190.HK)

致富證券Jun 22, 2021 00:00